Ibogaine neurotoxicity: a re-evaluation

Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hear...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain research 1996-10, Vol.737 (1), p.255-262
Hauptverfasser: Molinari, H.H, Maisonneuve, I.M, Glick, S.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 262
container_issue 1
container_start_page 255
container_title Brain research
container_volume 737
creator Molinari, H.H
Maisonneuve, I.M
Glick, S.D
description Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 × 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and ‘anti-addictive’ properties of ibogaine reflect different actions of the drug.
doi_str_mv 10.1016/0006-8993(96)00739-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15747544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006899396007391</els_id><sourcerecordid>15747544</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-872beb43f9de60e0f85eb133eeca011b4e168d45d7c2373b1f3e83cab3c7ad3c3</originalsourceid><addsrcrecordid>eNp9UMtKAzEUDaLUWv0Dha58LEaT3swjLgQpPgoFN7oOedyRyHSiyUyxf2-Gli5dXQ73PDiHkHNGbxllxR2ltMgqIeBaFDeUliAydkDGrCpnWTHj9JCM95RjchLjV4IAgo7IqBJAoYQxuVpo_6lci9MW--A7_-uM6zb3UzUNmOFaNb3qnG9PyVGtmohnuzshH89P7_PXbPn2spg_LjPDgXdZytaoOdTCYkGR1lWOmgEgGkUZ0xxZUVme29LMUr5mNWAFRmkwpbJgYEIut77fwf_0GDu5ctFg06gWfR8ly0te5pwnIt8STfAxBqzld3ArFTaSUTnsI4fycigvxQDSPpIl2cXOv9crtHvRbpD0f9j-MZVcOwwyGoetQesCmk5a7_4P-AOKc3Pa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15747544</pqid></control><display><type>article</type><title>Ibogaine neurotoxicity: a re-evaluation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Molinari, H.H ; Maisonneuve, I.M ; Glick, S.D</creator><creatorcontrib>Molinari, H.H ; Maisonneuve, I.M ; Glick, S.D</creatorcontrib><description>Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 × 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and ‘anti-addictive’ properties of ibogaine reflect different actions of the drug.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/0006-8993(96)00739-1</identifier><identifier>PMID: 8930373</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antibody Specificity ; Cerebellum ; Cerebellum - cytology ; Cerebellum - drug effects ; Dose-Response Relationship, Drug ; Evaluation Studies as Topic ; Female ; Fink-Heimer stain ; Glial fibrillary acidic protein ; Glial Fibrillary Acidic Protein - analysis ; Hallucinogens - toxicity ; Ibogaine ; Ibogaine - toxicity ; Nerve Degeneration - drug effects ; Nerve Tissue Proteins - analysis ; Nerve Tissue Proteins - immunology ; Neuroglia - chemistry ; Neuroglia - drug effects ; Neurotoxicity ; Neurotoxins - pharmacology ; Purkinje cell ; Purkinje Cells - drug effects ; Rats ; Rats, Sprague-Dawley ; Silver Staining ; Zebrin</subject><ispartof>Brain research, 1996-10, Vol.737 (1), p.255-262</ispartof><rights>1996 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-872beb43f9de60e0f85eb133eeca011b4e168d45d7c2373b1f3e83cab3c7ad3c3</citedby><cites>FETCH-LOGICAL-c434t-872beb43f9de60e0f85eb133eeca011b4e168d45d7c2373b1f3e83cab3c7ad3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0006899396007391$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8930373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Molinari, H.H</creatorcontrib><creatorcontrib>Maisonneuve, I.M</creatorcontrib><creatorcontrib>Glick, S.D</creatorcontrib><title>Ibogaine neurotoxicity: a re-evaluation</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 × 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and ‘anti-addictive’ properties of ibogaine reflect different actions of the drug.</description><subject>Animals</subject><subject>Antibody Specificity</subject><subject>Cerebellum</subject><subject>Cerebellum - cytology</subject><subject>Cerebellum - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Fink-Heimer stain</subject><subject>Glial fibrillary acidic protein</subject><subject>Glial Fibrillary Acidic Protein - analysis</subject><subject>Hallucinogens - toxicity</subject><subject>Ibogaine</subject><subject>Ibogaine - toxicity</subject><subject>Nerve Degeneration - drug effects</subject><subject>Nerve Tissue Proteins - analysis</subject><subject>Nerve Tissue Proteins - immunology</subject><subject>Neuroglia - chemistry</subject><subject>Neuroglia - drug effects</subject><subject>Neurotoxicity</subject><subject>Neurotoxins - pharmacology</subject><subject>Purkinje cell</subject><subject>Purkinje Cells - drug effects</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Silver Staining</subject><subject>Zebrin</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMtKAzEUDaLUWv0Dha58LEaT3swjLgQpPgoFN7oOedyRyHSiyUyxf2-Gli5dXQ73PDiHkHNGbxllxR2ltMgqIeBaFDeUliAydkDGrCpnWTHj9JCM95RjchLjV4IAgo7IqBJAoYQxuVpo_6lci9MW--A7_-uM6zb3UzUNmOFaNb3qnG9PyVGtmohnuzshH89P7_PXbPn2spg_LjPDgXdZytaoOdTCYkGR1lWOmgEgGkUZ0xxZUVme29LMUr5mNWAFRmkwpbJgYEIut77fwf_0GDu5ctFg06gWfR8ly0te5pwnIt8STfAxBqzld3ArFTaSUTnsI4fycigvxQDSPpIl2cXOv9crtHvRbpD0f9j-MZVcOwwyGoetQesCmk5a7_4P-AOKc3Pa</recordid><startdate>19961021</startdate><enddate>19961021</enddate><creator>Molinari, H.H</creator><creator>Maisonneuve, I.M</creator><creator>Glick, S.D</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19961021</creationdate><title>Ibogaine neurotoxicity: a re-evaluation</title><author>Molinari, H.H ; Maisonneuve, I.M ; Glick, S.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-872beb43f9de60e0f85eb133eeca011b4e168d45d7c2373b1f3e83cab3c7ad3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Antibody Specificity</topic><topic>Cerebellum</topic><topic>Cerebellum - cytology</topic><topic>Cerebellum - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Fink-Heimer stain</topic><topic>Glial fibrillary acidic protein</topic><topic>Glial Fibrillary Acidic Protein - analysis</topic><topic>Hallucinogens - toxicity</topic><topic>Ibogaine</topic><topic>Ibogaine - toxicity</topic><topic>Nerve Degeneration - drug effects</topic><topic>Nerve Tissue Proteins - analysis</topic><topic>Nerve Tissue Proteins - immunology</topic><topic>Neuroglia - chemistry</topic><topic>Neuroglia - drug effects</topic><topic>Neurotoxicity</topic><topic>Neurotoxins - pharmacology</topic><topic>Purkinje cell</topic><topic>Purkinje Cells - drug effects</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Silver Staining</topic><topic>Zebrin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Molinari, H.H</creatorcontrib><creatorcontrib>Maisonneuve, I.M</creatorcontrib><creatorcontrib>Glick, S.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Molinari, H.H</au><au>Maisonneuve, I.M</au><au>Glick, S.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibogaine neurotoxicity: a re-evaluation</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>1996-10-21</date><risdate>1996</risdate><volume>737</volume><issue>1</issue><spage>255</spage><epage>262</epage><pages>255-262</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><abstract>Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 × 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and ‘anti-addictive’ properties of ibogaine reflect different actions of the drug.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>8930373</pmid><doi>10.1016/0006-8993(96)00739-1</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-8993
ispartof Brain research, 1996-10, Vol.737 (1), p.255-262
issn 0006-8993
1872-6240
language eng
recordid cdi_proquest_miscellaneous_15747544
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Antibody Specificity
Cerebellum
Cerebellum - cytology
Cerebellum - drug effects
Dose-Response Relationship, Drug
Evaluation Studies as Topic
Female
Fink-Heimer stain
Glial fibrillary acidic protein
Glial Fibrillary Acidic Protein - analysis
Hallucinogens - toxicity
Ibogaine
Ibogaine - toxicity
Nerve Degeneration - drug effects
Nerve Tissue Proteins - analysis
Nerve Tissue Proteins - immunology
Neuroglia - chemistry
Neuroglia - drug effects
Neurotoxicity
Neurotoxins - pharmacology
Purkinje cell
Purkinje Cells - drug effects
Rats
Rats, Sprague-Dawley
Silver Staining
Zebrin
title Ibogaine neurotoxicity: a re-evaluation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T21%3A13%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibogaine%20neurotoxicity:%20a%20re-evaluation&rft.jtitle=Brain%20research&rft.au=Molinari,%20H.H&rft.date=1996-10-21&rft.volume=737&rft.issue=1&rft.spage=255&rft.epage=262&rft.pages=255-262&rft.issn=0006-8993&rft.eissn=1872-6240&rft_id=info:doi/10.1016/0006-8993(96)00739-1&rft_dat=%3Cproquest_cross%3E15747544%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15747544&rft_id=info:pmid/8930373&rft_els_id=0006899396007391&rfr_iscdi=true